Christopher D Lao

Summary

Affiliation: University of Michigan
Country: USA

Publications

  1. ncbi Dose escalation of a curcuminoid formulation
    Christopher D Lao
    Division of Hematology Oncology, Department of Internal Medicine, University of Michigan, 2150 CCGC, Ann Arbor, MI 48109 0930, USA
    BMC Complement Altern Med 6:10. 2006
  2. ncbi Targeting events in melanoma carcinogenesis for the prevention of melanoma
    Christopher D Lao
    University of Michigan, 1500 East Medical Center DriveAnn Arbor, MI 48109 0848, USA
    Expert Rev Anticancer Ther 6:1559-68. 2006
  3. ncbi Features predicting sentinel lymph node positivity in Merkel cell carcinoma
    Jennifer L Schwartz
    University of Michigan Health System, 1910 Taubman Center, 1500 E Medical Center Dr, Ann Arbor, MI 48109 0314, USA
    J Clin Oncol 29:1036-41. 2011
  4. ncbi Irreversible ototoxicity associated with difluoromethylornithine
    Christopher D Lao
    Department of Internal Medicine, University of Michigan Medical Center, Ann Arbor, 48109, USA
    Cancer Epidemiol Biomarkers Prev 13:1250-2. 2004
  5. ncbi Dysplasia in Barrett esophagus
    Christopher D Lao
    Department of Internal Medicine, University of Michigan Medical Center, Ann Arbor, Michigan 48109, USA
    Cancer 100:1622-7. 2004
  6. ncbi Strategies for prevention of colorectal cancer: pharmaceutical and nutritional interventions
    Christopher D Lao
    University of Michigan, 2150 Cancer Center and Geriatrics Center, Ann Arbor, MI 48109 USA
    Curr Treat Options Oncol 5:417-26. 2004
  7. ncbi Merkel cell carcinoma: critical review with guidelines for multidisciplinary management
    Christopher K Bichakjian
    Department of Dermatology, University of Michigan Health System, Ann Arbor, Michigan 48109 0314, USA
    Cancer 110:1-12. 2007
  8. ncbi Case 19-2008: Merkel-cell carcinoma
    Sandra L Wong
    N Engl J Med 359:1630; author reply 1630-1. 2008

Research Grants

  1. Development of a Melanoma Chemoprevention Model
    CHRISTOPHER LAO; Fiscal Year: 2007

Collaborators

Detail Information

Publications8

  1. ncbi Dose escalation of a curcuminoid formulation
    Christopher D Lao
    Division of Hematology Oncology, Department of Internal Medicine, University of Michigan, 2150 CCGC, Ann Arbor, MI 48109 0930, USA
    BMC Complement Altern Med 6:10. 2006
    ..However, few systematic studies of curcumin's pharmacology and toxicology in humans have been performed...
  2. ncbi Targeting events in melanoma carcinogenesis for the prevention of melanoma
    Christopher D Lao
    University of Michigan, 1500 East Medical Center DriveAnn Arbor, MI 48109 0848, USA
    Expert Rev Anticancer Ther 6:1559-68. 2006
    ..We will review the data for several promising agents, including statins, curcumin, resveratrol, silymarin and green tea, and discuss some importance issues and concepts that should be considered in any melanoma chemoprevention strategy...
  3. ncbi Features predicting sentinel lymph node positivity in Merkel cell carcinoma
    Jennifer L Schwartz
    University of Michigan Health System, 1910 Taubman Center, 1500 E Medical Center Dr, Ann Arbor, MI 48109 0314, USA
    J Clin Oncol 29:1036-41. 2011
    ..Merkel cell carcinoma (MCC) is a relatively rare, potentially aggressive cutaneous malignancy. We examined the clinical and histologic features of primary MCC that may correlate with the probability of a positive sentinel lymph node (SLN)...
  4. ncbi Irreversible ototoxicity associated with difluoromethylornithine
    Christopher D Lao
    Department of Internal Medicine, University of Michigan Medical Center, Ann Arbor, 48109, USA
    Cancer Epidemiol Biomarkers Prev 13:1250-2. 2004
    ..This is the first case reported of irreversible ototoxicity in a clinical trial participant receiving DFMO and, thus, trial participants should be made aware of this small but important risk...
  5. ncbi Dysplasia in Barrett esophagus
    Christopher D Lao
    Department of Internal Medicine, University of Michigan Medical Center, Ann Arbor, Michigan 48109, USA
    Cancer 100:1622-7. 2004
    ..CONCLUSIONS: The confirmed low prevalence of cases of LGD will affect the design of future clinical trials of chemopreventive interventions for Barrett esophagus...
  6. ncbi Strategies for prevention of colorectal cancer: pharmaceutical and nutritional interventions
    Christopher D Lao
    University of Michigan, 2150 Cancer Center and Geriatrics Center, Ann Arbor, MI 48109 USA
    Curr Treat Options Oncol 5:417-26. 2004
    ....
  7. ncbi Merkel cell carcinoma: critical review with guidelines for multidisciplinary management
    Christopher K Bichakjian
    Department of Dermatology, University of Michigan Health System, Ann Arbor, Michigan 48109 0314, USA
    Cancer 110:1-12. 2007
    ..Finally, the authors have provided treatment guidelines based on the available evidence and their multidisciplinary experience...
  8. ncbi Case 19-2008: Merkel-cell carcinoma
    Sandra L Wong
    N Engl J Med 359:1630; author reply 1630-1. 2008

Research Grants2

  1. Development of a Melanoma Chemoprevention Model
    CHRISTOPHER LAO; Fiscal Year: 2007
    ..This line of investigation will help determine the importance of NF-kB and 12-LOX in melanoma carcinogenesis and provide an infrastructure for rapid testing of putative Chemoprevention agents and biomarkers in the future. ..